Research
Hormonal
Tirzepatide was associated with a significantly lower risk of all-cause mortality compared with bariatric metabolic surgery (BMS) (HR, 0.311; 95% CI, 0.257-0.375; p < 0.0001).
Tirzepatide may be a safer option for reducing mortality in obese patients compared to surgical interventions.
StrongSupportsmedium confidence
Tirzepatide was associated with a significantly lower risk of all-cause mortality compared with BMS (HR, 0.311; 95% CI, 0.257-0.375; p < 0.0001).
Why this rating
The study involves a large sample size with propensity score matching.
Source
Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study
Jheng‐Yan Wu et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16353
cohort · n=168968Cited 14×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →